Siasos, Gerasimos

2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 4,763

2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,642

Mitochondria and cardiovascular diseases-from pathophysiology to treatment

Siasos, G., Tsigkou, V., Kosmopoulos, M., Theodosiadis, D., Simantiris, S., Tagkou, N. M., Tsimpiktsioglou, A., Stampouloglou, P. K., Oikonomou, E., Mourouzis, K., et al. (2018) · Annals of Translational Medicine

Mitochondrial Function and PathologyCardiac Ischemia and Reperfusion

Cited by 245

Cardiovascular effects of electronic cigarettes: a systematic review and meta-analysis

Skotsimara, G., Antonopoulos, A. S., Oikonomou, E., Siasos, G., Ioakeimidis, N., Tsalamandris, S., Charalambous, G., Galiatsatos, N., Vlachopoulos, C., & Tousoulis, D. (2019) · European Journal of Preventive Cardiology

Smoking Behavior and CessationCardiovascular Health and Disease Prevention

Cited by 190

Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes

Bakogiannis, C., Tousoulis, D., Androulakis, E., Briasoulis, A., Papageorgiou, N., Vogiatzi, G., Kampoli, A.-M., Charakida, M., Siasos, G., Latsios, G., et al. (2012) · Current Medicinal Chemistry

Angiogenesis and VEGF in CancerNitric Oxide and Endothelin Effects

Cited by 71

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis

Stefanou, M.-I., Theodorou, A., Malhotra, K., Aguiar de Sousa, D., Katan, M., Palaiodimou, L., Katsanos, A. H., Koutroulou, I., Lambadiari, V., Lemmens, R., et al. (2024) · European Stroke Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 60

Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis

Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Semaglutide concurrently improves vascular and liver indices in patients with type 2 diabetes and fatty liver disease

Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., et al. (2024) · Journal of the Endocrine Society

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 18

Efficacy and Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta‐Analysis

Stefanou, M., Chatziralli, I., Lambadiari, V., Mengel, A., Foska, A., Chondrogianni, M., Bakola, E., Tsalouchidou, P., Mitsikostas, D. D., Siasos, G., et al. (2025) · European Journal of Neurology

Cerebral Venous Sinus ThrombosisGlaucoma and retinal disorders

Cited by 12